Compare PHR & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHR | DBVT |
|---|---|---|
| Founded | 2005 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 759.0M | 850.9M |
| IPO Year | 2019 | 2014 |
| Metric | PHR | DBVT |
|---|---|---|
| Price | $9.69 | $12.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 7 |
| Target Price | $21.18 | ★ $32.04 |
| AVG Volume (30 Days) | ★ 600.8K | 278.0K |
| Earning Date | 05-27-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 103.92 | 10.26 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $480,591,000.00 | $5,636,000.00 |
| Revenue This Year | $8.43 | $35.04 |
| Revenue Next Year | $5.10 | $2,360.78 |
| P/E Ratio | $126.25 | ★ N/A |
| Revenue Growth | 14.48 | ★ 35.77 |
| 52 Week Low | $7.77 | $8.86 |
| 52 Week High | $24.25 | $26.19 |
| Indicator | PHR | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 36.39 | N/A |
| Support Level | $9.67 | N/A |
| Resistance Level | $10.27 | N/A |
| Average True Range (ATR) | 0.32 | 0.00 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 13.44 | 0.00 |
Phreesia Inc is a provides an integrated software, payments, and engagement platform designed to address three foundational challenges in healthcare delivery: access to care, affordability of care, and patient health outcomes. Its platform is embedded directly into provider workflows and patient interactions, enabling healthcare organizations to activate patients, streamline administrative processes, and improve financial performance across the care continuum. The group serves a diverse group of healthcare organizations, including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest, and not-for-profit and other organizations.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.